Premium
Neuroleptic Malignant Syndrome Associated With Clozapine Monotherapy
Author(s) -
Thornberg Sheri A.,
Ereshefsky Larry
Publication year - 1993
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1993.tb04317.x
Subject(s) - clozapine , neuroleptic malignant syndrome , medicine , dopamine , dopamine receptor , striatum , dopamine receptor d2 , blockade , pharmacology , schizophrenia (object oriented programming) , oncology , psychology , receptor , psychiatry
Neuroleptic malignant syndrome is thought to be a result of dopamine receptor blockade in the striatum. Clozapine has only weak affinity for dopamine type 1 and 2 receptors, and therefore it was thought this drug would not precipitate the syndrome. However, six cases of the syndrome have been reported in patients receiving clozapine monotherapy. A review of the pathoetiology of symptoms occurring in the syndrome is included.